Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial
A prospective decision-aiding trial was performed to select drugs for regional chemotherapy of various liver tumors (n = 36) by individual drug testing. The drugs were chosen for hepatic artery infusion according to the individual chemosensitivity of tumor biopsies in the human tumor colony-forming...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 1996-09, Vol.2 (9), p.1469-1474 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1474 |
|---|---|
| container_issue | 9 |
| container_start_page | 1469 |
| container_title | Clinical cancer research |
| container_volume | 2 |
| creator | LINK, K. H KORNMANN, M LEDER, G. H BUTZER, U PILLASCH, J STAIB, L GANSAUGE, F BEGER, H. G |
| description | A prospective decision-aiding trial was performed to select drugs for regional chemotherapy of various liver tumors (n = 36)
by individual drug testing. The drugs were chosen for hepatic artery infusion according to the individual chemosensitivity
of tumor biopsies in the human tumor colony-forming assay (HTCA). In vitro HTCA sensitivity correlated with complete response
(CR) + partial response (PR) + no change (NC) 93% of the time and with CR + PR 55% of the time. The test sensitivity was 90%,
and the specificity was 67% for CR + PR + NC versus progressive disease (PD), whereas the sensitivity and specificity were
89% and 28%, respectively, for CR + PR versus NC + PD. The overall predictive accuracy of the test was 86% for CR + PR + NC
versus PD and 58% for CR + PR versus NC + PD. Overall, 83% of this heterogenous patient group with various tumors achieved
CR + PR + NC and a 50% clinical response (CR + PR). In vitro-sensitive patients showed a significantly lower intrahepatic
progression rate (7% PD) than in vitro-resistant patients (57%; P < 0.05). These results indicate that the HTCA could identify
active drugs for individualized hepatic artery infusion, and patients may profit from the use of in vitro-sensitive drugs. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78765249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78765249</sourcerecordid><originalsourceid>FETCH-LOGICAL-h182t-6831f8e6979c137b214dcd9642b735553993999e7a4955928427631e2e568e863</originalsourceid><addsrcrecordid>eNo90FlLxDAQAOAiyrqu_gQhD6JPheZOfJPFCxYE0eeSJrPbSI81aVf6741YhUCO-WaYzFG2xJzLnBLBj9O5kCovGCWn2VmMH0WBGS7YIltohQUlZJnFV9j5vjMNsjW0_VBDMPsJOR_ADuBQNSHfOX_wbvwzEbroh_Q0TGiAOPhulwxK99DfIoP2oY_7lO0PgBxYH1P93Hj344bgTXOenWxNE-Fi3lfZ-8P92_op37w8Pq_vNnmNFRlyoSjeKhBaaouprAhmzjotGKkk5ZxTrdPSIA3TnGuiGJGCYiDAhQIl6Cq7_q2bOvocU6dl66OFpjEd9GMspZKCE6YTvJzhWLXgyn3wrQlTOU8pxa_muInWNNtguvStf5aIopwmdvPLar-rv9IES5sghAARTLB1SUpdYiY0_QZbXn_F</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78765249</pqid></control><display><type>article</type><title>Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>LINK, K. H ; KORNMANN, M ; LEDER, G. H ; BUTZER, U ; PILLASCH, J ; STAIB, L ; GANSAUGE, F ; BEGER, H. G</creator><creatorcontrib>LINK, K. H ; KORNMANN, M ; LEDER, G. H ; BUTZER, U ; PILLASCH, J ; STAIB, L ; GANSAUGE, F ; BEGER, H. G</creatorcontrib><description>A prospective decision-aiding trial was performed to select drugs for regional chemotherapy of various liver tumors (n = 36)
by individual drug testing. The drugs were chosen for hepatic artery infusion according to the individual chemosensitivity
of tumor biopsies in the human tumor colony-forming assay (HTCA). In vitro HTCA sensitivity correlated with complete response
(CR) + partial response (PR) + no change (NC) 93% of the time and with CR + PR 55% of the time. The test sensitivity was 90%,
and the specificity was 67% for CR + PR + NC versus progressive disease (PD), whereas the sensitivity and specificity were
89% and 28%, respectively, for CR + PR versus NC + PD. The overall predictive accuracy of the test was 86% for CR + PR + NC
versus PD and 58% for CR + PR versus NC + PD. Overall, 83% of this heterogenous patient group with various tumors achieved
CR + PR + NC and a 50% clinical response (CR + PR). In vitro-sensitive patients showed a significantly lower intrahepatic
progression rate (7% PD) than in vitro-resistant patients (57%; P < 0.05). These results indicate that the HTCA could identify
active drugs for individualized hepatic artery infusion, and patients may profit from the use of in vitro-sensitive drugs.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 9816322</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Antidotes - therapeutic use ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Chemotherapy, Cancer, Regional Perfusion ; Cisplatin - therapeutic use ; Doxorubicin - analogs & derivatives ; Doxorubicin - therapeutic use ; Drug Therapy, Combination ; Female ; Fluorouracil - therapeutic use ; General aspects ; Humans ; Infusions, Intra-Arterial ; Leucovorin - therapeutic use ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; Mitomycin - therapeutic use ; Mitoxantrone - therapeutic use ; Neoplastic Stem Cells - drug effects ; Pharmacology. Drug treatments ; Prospective Studies ; Tumor Stem Cell Assay</subject><ispartof>Clinical cancer research, 1996-09, Vol.2 (9), p.1469-1474</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3228353$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9816322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LINK, K. H</creatorcontrib><creatorcontrib>KORNMANN, M</creatorcontrib><creatorcontrib>LEDER, G. H</creatorcontrib><creatorcontrib>BUTZER, U</creatorcontrib><creatorcontrib>PILLASCH, J</creatorcontrib><creatorcontrib>STAIB, L</creatorcontrib><creatorcontrib>GANSAUGE, F</creatorcontrib><creatorcontrib>BEGER, H. G</creatorcontrib><title>Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>A prospective decision-aiding trial was performed to select drugs for regional chemotherapy of various liver tumors (n = 36)
by individual drug testing. The drugs were chosen for hepatic artery infusion according to the individual chemosensitivity
of tumor biopsies in the human tumor colony-forming assay (HTCA). In vitro HTCA sensitivity correlated with complete response
(CR) + partial response (PR) + no change (NC) 93% of the time and with CR + PR 55% of the time. The test sensitivity was 90%,
and the specificity was 67% for CR + PR + NC versus progressive disease (PD), whereas the sensitivity and specificity were
89% and 28%, respectively, for CR + PR versus NC + PD. The overall predictive accuracy of the test was 86% for CR + PR + NC
versus PD and 58% for CR + PR versus NC + PD. Overall, 83% of this heterogenous patient group with various tumors achieved
CR + PR + NC and a 50% clinical response (CR + PR). In vitro-sensitive patients showed a significantly lower intrahepatic
progression rate (7% PD) than in vitro-resistant patients (57%; P < 0.05). These results indicate that the HTCA could identify
active drugs for individualized hepatic artery infusion, and patients may profit from the use of in vitro-sensitive drugs.</description><subject>Adult</subject><subject>Aged</subject><subject>Antidotes - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy, Cancer, Regional Perfusion</subject><subject>Cisplatin - therapeutic use</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>General aspects</subject><subject>Humans</subject><subject>Infusions, Intra-Arterial</subject><subject>Leucovorin - therapeutic use</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mitomycin - therapeutic use</subject><subject>Mitoxantrone - therapeutic use</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Tumor Stem Cell Assay</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90FlLxDAQAOAiyrqu_gQhD6JPheZOfJPFCxYE0eeSJrPbSI81aVf6741YhUCO-WaYzFG2xJzLnBLBj9O5kCovGCWn2VmMH0WBGS7YIltohQUlZJnFV9j5vjMNsjW0_VBDMPsJOR_ADuBQNSHfOX_wbvwzEbroh_Q0TGiAOPhulwxK99DfIoP2oY_7lO0PgBxYH1P93Hj344bgTXOenWxNE-Fi3lfZ-8P92_op37w8Pq_vNnmNFRlyoSjeKhBaaouprAhmzjotGKkk5ZxTrdPSIA3TnGuiGJGCYiDAhQIl6Cq7_q2bOvocU6dl66OFpjEd9GMspZKCE6YTvJzhWLXgyn3wrQlTOU8pxa_muInWNNtguvStf5aIopwmdvPLar-rv9IES5sghAARTLB1SUpdYiY0_QZbXn_F</recordid><startdate>199609</startdate><enddate>199609</enddate><creator>LINK, K. H</creator><creator>KORNMANN, M</creator><creator>LEDER, G. H</creator><creator>BUTZER, U</creator><creator>PILLASCH, J</creator><creator>STAIB, L</creator><creator>GANSAUGE, F</creator><creator>BEGER, H. G</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199609</creationdate><title>Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial</title><author>LINK, K. H ; KORNMANN, M ; LEDER, G. H ; BUTZER, U ; PILLASCH, J ; STAIB, L ; GANSAUGE, F ; BEGER, H. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h182t-6831f8e6979c137b214dcd9642b735553993999e7a4955928427631e2e568e863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antidotes - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy, Cancer, Regional Perfusion</topic><topic>Cisplatin - therapeutic use</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>General aspects</topic><topic>Humans</topic><topic>Infusions, Intra-Arterial</topic><topic>Leucovorin - therapeutic use</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mitomycin - therapeutic use</topic><topic>Mitoxantrone - therapeutic use</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Tumor Stem Cell Assay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LINK, K. H</creatorcontrib><creatorcontrib>KORNMANN, M</creatorcontrib><creatorcontrib>LEDER, G. H</creatorcontrib><creatorcontrib>BUTZER, U</creatorcontrib><creatorcontrib>PILLASCH, J</creatorcontrib><creatorcontrib>STAIB, L</creatorcontrib><creatorcontrib>GANSAUGE, F</creatorcontrib><creatorcontrib>BEGER, H. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LINK, K. H</au><au>KORNMANN, M</au><au>LEDER, G. H</au><au>BUTZER, U</au><au>PILLASCH, J</au><au>STAIB, L</au><au>GANSAUGE, F</au><au>BEGER, H. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>1996-09</date><risdate>1996</risdate><volume>2</volume><issue>9</issue><spage>1469</spage><epage>1474</epage><pages>1469-1474</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>A prospective decision-aiding trial was performed to select drugs for regional chemotherapy of various liver tumors (n = 36)
by individual drug testing. The drugs were chosen for hepatic artery infusion according to the individual chemosensitivity
of tumor biopsies in the human tumor colony-forming assay (HTCA). In vitro HTCA sensitivity correlated with complete response
(CR) + partial response (PR) + no change (NC) 93% of the time and with CR + PR 55% of the time. The test sensitivity was 90%,
and the specificity was 67% for CR + PR + NC versus progressive disease (PD), whereas the sensitivity and specificity were
89% and 28%, respectively, for CR + PR versus NC + PD. The overall predictive accuracy of the test was 86% for CR + PR + NC
versus PD and 58% for CR + PR versus NC + PD. Overall, 83% of this heterogenous patient group with various tumors achieved
CR + PR + NC and a 50% clinical response (CR + PR). In vitro-sensitive patients showed a significantly lower intrahepatic
progression rate (7% PD) than in vitro-resistant patients (57%; P < 0.05). These results indicate that the HTCA could identify
active drugs for individualized hepatic artery infusion, and patients may profit from the use of in vitro-sensitive drugs.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9816322</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 1996-09, Vol.2 (9), p.1469-1474 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78765249 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antidotes - therapeutic use Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy, Cancer, Regional Perfusion Cisplatin - therapeutic use Doxorubicin - analogs & derivatives Doxorubicin - therapeutic use Drug Therapy, Combination Female Fluorouracil - therapeutic use General aspects Humans Infusions, Intra-Arterial Leucovorin - therapeutic use Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Medical sciences Middle Aged Mitomycin - therapeutic use Mitoxantrone - therapeutic use Neoplastic Stem Cells - drug effects Pharmacology. Drug treatments Prospective Studies Tumor Stem Cell Assay |
| title | Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T14%3A49%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regional%20chemotherapy%20directed%20by%20individual%20chemosensitivity%20testing%20in%20vitro:%20a%20prospective%20decision-aiding%20trial&rft.jtitle=Clinical%20cancer%20research&rft.au=LINK,%20K.%20H&rft.date=1996-09&rft.volume=2&rft.issue=9&rft.spage=1469&rft.epage=1474&rft.pages=1469-1474&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E78765249%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78765249&rft_id=info:pmid/9816322&rfr_iscdi=true |